quinazolines has been researched along with ipi-145 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, M; Frenzel, LP; Göckeritz, E; Hallek, M; Kerwien, S; Klein, C; Krause, G; Landwehr, T; Liu, N; Neumann, L; Vondey, V; Wendtner, CM; Wigger, M | 1 |
| Kim, JH; Kim, WS; Park, C | 1 |
| Dittakavi, S; Kumar, R; Mullangi, R; Siddesh, A; Sriram, D; Trivedi, RK; Zainuddin, M; Zakkula, A | 1 |
| Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J | 1 |
1 review(s) available for quinazolines and ipi-145
| Article | Year |
|---|---|
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-
Topics: Benzamides; Biphenyl Compounds; Child, Preschool; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Lymphoma, Follicular; Morpholines; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Purines; Pyridones; Pyrimidines; Quinazolines; Quinazolinones; Risk | 2022 |
3 other study(ies) available for quinazolines and ipi-145
| Article | Year |
|---|---|
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Isoenzymes; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rituximab; Signal Transduction | 2015 |
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Topics: Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Interleukin-6; Isoquinolines; Janus Kinase Inhibitors; Lymphoma, B-Cell; Lymphoma, T-Cell; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; STAT3 Transcription Factor; STAT5 Transcription Factor; Transfection; Tumor Suppressor Proteins | 2019 |
Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Isoquinolines; Linear Models; Liquid-Liquid Extraction; Male; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2021 |